Alembic Pharmaceuticals Performance
- Today's Low
- ₹770
- Today's High
- ₹785
- 52 Week Low
- ₹636
- 52 Week High
- ₹1,108
- Open Price₹771
- Previous Close₹777
- Volume17,213
- 50 DMA₹748.70
- 100 DMA₹762.10
- 200 DMA₹804.61
Alembic Pharmaceuticals Chart
Investment Returns
- Over 1 Month + 3.05%
- Over 3 Month + 20.45%
- Over 6 Month -9.17%
- Over 1 Year -17.12%
Smart Investing Starts Here Start SIP with Alembic Pharmaceuticals for Steady Growth!
Alembic Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 22.7
- PEG Ratio
- 1.4
- Market Cap Cr
- 15,307
- P/B Ratio
- 2.7
- Average True Range
- 22.64
- EPS
- 37.11
- Dividend Yield
- 1.4
- MACD Signal
- -0.17
- RSI
- 61.72
- MFI
- 89.75
Latest Stock News Updates
USFDA's tentative approval is for the ANDA of Binimetinib tablets of strength 45 mg
- Business Line
- 4 days 23 hours ago
Alembic Pharmaceuticals Ltd on Friday said it has received final approval from the US health regulator for its generic version of levothyroxine sodium tablet indicated as a replacement therapy for hypothyroidism. The approval by the US Food & Drug Administration (USFDA) is for the Abbreviated New Drug Application (ANDA) of levothyroxine sodium tablets of strengths 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg and 300 mcg, Alembic said in a regulatory filing. The approved ANDA is therapeutically equivalent to the reference listed drug product, Synthroid tablets, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg and 300 mcg, of AbbVie, Inc, it added. Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism, the company said. Levothyroxine sodium tablets are indicated as .
- Business Standard
- 1 month ago
Alembic Pharmaceuticals reported a 29 per cent year-on-year (Y-o-Y) rise in consolidated net profit to 202 crore as compared to 157 crore in the year-ago period
- Business Standard
- 1 month ago
Alembic Pharmaceuticals Financials
Alembic Pharmaceuticals Technicals
EMA & SMA
- Bearish Moving Average 3
- Bullish Moving Average 13
- 20 Day
- ₹751.60
- 50 Day
- ₹748.70
- 100 Day
- ₹762.10
- 200 Day
- ₹804.60
Resistance and Support
- R3 806.08
- R2 799.47
- R1 788.23
- S1 770.38
- S2 763.77
- S3 752.53
Alembic Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-05-15 | Audited Results & Final Dividend | |
| 2026-02-05 | Quarterly Results | |
| 2025-11-04 | Quarterly Results & Others | To consider other business matters. per share(700%)Dividend |
| 2025-08-05 | Quarterly Results & Others | To consider other business matters. per share(700%)Dividend |
| 2025-05-06 | Audited Results & Final Dividend |
About Alembic Pharmaceuticals
- NSE Symbol
- APLLTD
- BSE Symbol
- 533573
- Managing Director
- Mr. Pranav Amin
- ISIN
- INE901L01018
Similar Stocks to Alembic Pharmaceuticals
Popular Stocks
Alembic Pharmaceuticals FAQs
Alembic Pharmaceuticals share price is ₹778 As on 24 June, 2026 | 13:56
The Market Cap of Alembic Pharmaceuticals is ₹15307.4 Cr As on 24 June, 2026 | 13:56
The P/E ratio of Alembic Pharmaceuticals is 22.7 As on 24 June, 2026 | 13:56
The PB ratio of Alembic Pharmaceuticals is 2.7 As on 24 June, 2026 | 13:56
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.